左甲状腺素钠联合阿仑膦酸钠对甲状腺功能减退患者心肌酶谱、ⅠCTP、BGP、ALP及对氧磷酶1含量的影响分析
|
摘要
目的:探讨左甲状腺素钠联合阿仑膦酸钠对甲状腺功能减退患者心肌酶谱(AST、CK、LDH)、骨代谢指标(ⅠCTP、BGP、ALP)、对氧磷酶1(PON1)含量的影响。方法:选取2016年1月-2017年1月本院收治的80例甲状腺功能减退患者的临床资料进行回顾性分析。依据不同治疗方式将其分为对照组和试验组,各40例。对照组给予左甲状腺素钠治疗,试验组予以左甲状腺素钠联合阿仑膦酸钠治疗。比较两组治疗前后的心肌酶谱、骨代谢指标、PON1含量。结果:治疗后,试验组AST、CK、LDH水平均低于对照组,ⅠCTP、BGP、ALP、PON1水平均高于对照组,差异均有统计学意义(P<0.05)。结论:左甲状腺素钠联合阿仑膦酸钠治疗甲状腺功能减退可有效改善患者心肌酶谱、骨代谢指标水平,提升PON1含量,值得选用。
Objective:To investigate the effects of Levothyroxine Sodium combined with Alendronate Sodium on myocardial enzymes(AST,CK,LDH),bone metabolism indexes(ⅠCTP,BGP,ALP)and paraoxonase 1(PON1)in patients with hypothyroidism.Method:Clinical data of 80 patients with hypothyroidism admitted to our hospital from January 2016 to January 2017 were retrospectively analyzed.According to different treatment methods,they were divided into control group and experimental group,40 cases in each group.The control group was treated with Levothyroxine Sodium,while experimental group was treated with Levothyroxine Sodium and Alendronate Sodium.The myocardial zymogram,bone metabolism index and PON1 content before and after treatment between two groups were compared.Result:After treatment,the levels of AST,CK and LDH in experimental group were lower than those of control group,and the levels of ⅠCTP,BGP,ALP and PON1 in experimental group were higher than those of control group,the differences were statistically significant(P<0.05).Conclusion:Levothyroxine Sodium combined with Alendronate Sodium in treatment of hypothyroidism can effectively improve the level of myocardial enzymes,bone metabolism indicators and increase the content of PON1,which is worthy of selection.
Objective:To investigate the effects of Levothyroxine Sodium combined with Alendronate Sodium on myocardial enzymes(AST,CK,LDH),bone metabolism indexes(ⅠCTP,BGP,ALP)and paraoxonase 1(PON1)in patients with hypothyroidism.Method:Clinical data of 80 patients with hypothyroidism admitted to our hospital from January 2016 to January 2017 were retrospectively analyzed.According to different treatment methods,they were divided into control group and experimental group,40 cases in each group.The control group was treated with Levothyroxine Sodium,while experimental group was treated with Levothyroxine Sodium and Alendronate Sodium.The myocardial zymogram,bone metabolism index and PON1 content before and after treatment between two groups were compared.Result:After treatment,the levels of AST,CK and LDH in experimental group were lower than those of control group,and the levels of ⅠCTP,BGP,ALP and PON1 in experimental group were higher than those of control group,the differences were statistically significant(P<0.05).Conclusion:Levothyroxine Sodium combined with Alendronate Sodium in treatment of hypothyroidism can effectively improve the level of myocardial enzymes,bone metabolism indicators and increase the content of PON1,which is worthy of selection.
引文
[1]程千鹏,洛佩,吕肖锋.甲状腺功能减退症的病因和对机体影响的研究进展[J].医学综述,2018,24(9):1766-1770.
[2]谢秋娴,杨纯谢,昭雄,等.妊娠合并甲状腺功能减退症经激素替代治疗的妊娠结局分析[J].河北医学,2016,22(1):89-92.
[3]Yang R,Yao L,Fang Y,et al.The relationship between subclinical thyroid dysfunction and the risk of fracture or low bone mineral density:a systematic review and meta-analysis of cohort studies[J].J Bone Miner Metab,2017,36(2):209-220.
[4]中华医学会内分泌学分会.成人甲状腺功能减退症诊治指南[J].中华内分泌代谢杂志,2017,33(2):167-180.
[5]王耀立,王明华,魏军平.160例亚临床甲状腺功能减退症患者临床特点初步分析[J].世界中西医结合杂志,2016,11(2):238-241.
[6]焦竞,李烨,王俊文,等.甲状腺功能异常患者血生化、骨代谢及骨密度特点的临床研究[J].中国骨质疏松杂志,2017,23(12):1600-1602,1659.
[7]周淼.高剂量左旋甲状腺素对妊娠合并甲减患者血脂及叶酸水平的影响[J].中国实验诊断学,2017,21(9):1530-1532.
[8]蒋晓霞,冷静,陆纪元,等.左旋甲状腺素钠片结合真武汤加味治疗甲状腺功能减退性心脏病临床观察[J].湖北中医药大学学报,2016,18(4):61-63.
[9]刘颖,马凤云.阿仑膦酸钠及唑来膦酸治疗原发性骨质疏松症患者的临床疗效研究[J].河北医学,2016,22(1):25-29.
[10]袁志峰,刘会文.唑来膦酸、伊班膦酸钠及阿伦膦酸钠防治绝经后骨质疏松症的疗效对比研究[J].中国骨质疏松杂志,2018,24(2):249-252,269.
[11]王思远,王文尧,唐熠达.甲状腺功能减退与急性心肌梗死患者不良心血管事件的相关性研究[J].中国循环杂志,2017,32(Z1):7.
[12]Gao X,Liu M,Qu A,et al.Native Magnetic Resonance T1-Mapping Identifies Diffuse Myocardial Injury in Hypothyroidism[J].PLoS One,2016,11(3):e0151266.
[13]唐翔,韩万伟,丁捷.妊娠期亚临床甲状腺功能减退女性骨密度及骨代谢生化指标分析[J].中国骨质疏松杂志,2017,23(12):1592-1595.
[14]姜国良,王萍.甲状腺功能减退对妊娠妇女骨代谢及骨密度的影响[J].安徽医药,2018,22(6):1109-1111.
[15]Ates I,Altay M,Yilmaz F M,et al.The Impact of Levothyroxine Sodium Treatment on Oxidative Stress in Hashimoto’s Thyroiditis[J].Eur J Endocrinol,2016,174(6):727-734.
[16]寿盼盼,潘天荣,钟兴,等.儿茶素和左甲状腺素钠对甲状腺功能减退大鼠抗氧化应激能力改善的影响[J].安徽医科大学学报,2017,52(3):365-368.
[17]黄水英,李家富.髓过氧化物酶/对氧磷酶-1对高密度脂蛋白功能及冠心病危险评估的预测意义[J].当代医学,2017,23(7):182-184.
[18]李招霞,赵会文,苏宁,等.甲状腺癌术后短期甲状腺功能低下对骨代谢的影响[J].现代生物医学进展,2016,16(24):4647-4650.
[19]李秀芬,孙太冉,王玮,等.甲状腺功能亢进症患者骨代谢指标及白细胞介素-6水平变化的研究[J].中国临床医生杂志,2017,45(1):33-35.
[20]苏秀英.甲状腺功能亢进症患者相关代谢指标变化分析[J/OL].临床医药文献电子杂志,2016,3(8):1466-1467.
[2]谢秋娴,杨纯谢,昭雄,等.妊娠合并甲状腺功能减退症经激素替代治疗的妊娠结局分析[J].河北医学,2016,22(1):89-92.
[3]Yang R,Yao L,Fang Y,et al.The relationship between subclinical thyroid dysfunction and the risk of fracture or low bone mineral density:a systematic review and meta-analysis of cohort studies[J].J Bone Miner Metab,2017,36(2):209-220.
[4]中华医学会内分泌学分会.成人甲状腺功能减退症诊治指南[J].中华内分泌代谢杂志,2017,33(2):167-180.
[5]王耀立,王明华,魏军平.160例亚临床甲状腺功能减退症患者临床特点初步分析[J].世界中西医结合杂志,2016,11(2):238-241.
[6]焦竞,李烨,王俊文,等.甲状腺功能异常患者血生化、骨代谢及骨密度特点的临床研究[J].中国骨质疏松杂志,2017,23(12):1600-1602,1659.
[7]周淼.高剂量左旋甲状腺素对妊娠合并甲减患者血脂及叶酸水平的影响[J].中国实验诊断学,2017,21(9):1530-1532.
[8]蒋晓霞,冷静,陆纪元,等.左旋甲状腺素钠片结合真武汤加味治疗甲状腺功能减退性心脏病临床观察[J].湖北中医药大学学报,2016,18(4):61-63.
[9]刘颖,马凤云.阿仑膦酸钠及唑来膦酸治疗原发性骨质疏松症患者的临床疗效研究[J].河北医学,2016,22(1):25-29.
[10]袁志峰,刘会文.唑来膦酸、伊班膦酸钠及阿伦膦酸钠防治绝经后骨质疏松症的疗效对比研究[J].中国骨质疏松杂志,2018,24(2):249-252,269.
[11]王思远,王文尧,唐熠达.甲状腺功能减退与急性心肌梗死患者不良心血管事件的相关性研究[J].中国循环杂志,2017,32(Z1):7.
[12]Gao X,Liu M,Qu A,et al.Native Magnetic Resonance T1-Mapping Identifies Diffuse Myocardial Injury in Hypothyroidism[J].PLoS One,2016,11(3):e0151266.
[13]唐翔,韩万伟,丁捷.妊娠期亚临床甲状腺功能减退女性骨密度及骨代谢生化指标分析[J].中国骨质疏松杂志,2017,23(12):1592-1595.
[14]姜国良,王萍.甲状腺功能减退对妊娠妇女骨代谢及骨密度的影响[J].安徽医药,2018,22(6):1109-1111.
[15]Ates I,Altay M,Yilmaz F M,et al.The Impact of Levothyroxine Sodium Treatment on Oxidative Stress in Hashimoto’s Thyroiditis[J].Eur J Endocrinol,2016,174(6):727-734.
[16]寿盼盼,潘天荣,钟兴,等.儿茶素和左甲状腺素钠对甲状腺功能减退大鼠抗氧化应激能力改善的影响[J].安徽医科大学学报,2017,52(3):365-368.
[17]黄水英,李家富.髓过氧化物酶/对氧磷酶-1对高密度脂蛋白功能及冠心病危险评估的预测意义[J].当代医学,2017,23(7):182-184.
[18]李招霞,赵会文,苏宁,等.甲状腺癌术后短期甲状腺功能低下对骨代谢的影响[J].现代生物医学进展,2016,16(24):4647-4650.
[19]李秀芬,孙太冉,王玮,等.甲状腺功能亢进症患者骨代谢指标及白细胞介素-6水平变化的研究[J].中国临床医生杂志,2017,45(1):33-35.
[20]苏秀英.甲状腺功能亢进症患者相关代谢指标变化分析[J/OL].临床医药文献电子杂志,2016,3(8):1466-1467.